Drug makers stop top dosage in Alzheimer's trial

Forbes
By SHAWN POGATCHNIK , 04.02.09, 05:49 AM EDT

The developers of an experimental new treatment for Alzheimer's disease, and Wyeth, announced Thursday they have stopped the top dosage because trial patients are suffering from an increased risk of brain inflammation from water retention.

The companies said the setback would not affect their ongoing, advanced trials to win approval for bapineuzumab, a drug designed to combat Alzheimer's, an incurable disease that destroys the brain.

"Our review of the safety data and the feedback from the Safety Monitoring Committee made it clear....read the whole article

For more dementia information, click here

For Alzheimer's and dementia activities, click here

For information on being the best caregiver you can be, click here

For a great resource for those with dementia, caregivers and healthcare professinals, click here